• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The costs associated with stroke care continuum: a systematic review
Stroke, a leading cause of death and long-term disability, has a considerable social and economic impact. It is imperative to investigate stroke-related costs. The main goal was to conduct a systematic literat...
Source: Health Economics Review - May 17, 2023 Category: Health Management Authors: Jorgina Lucas-Noll, Jos é L. Clua-Espuny, Mar Lleixà-Fortuño, Ester Gavaldà-Espelta, Lluïsa Queralt-Tomas, Anna Panisello-Tafalla and Misericòrdia Carles-Lavila Tags: Review Source Type: research

Cost-effectiveness of a photopethysmographic procedure for screening for atrial fibrillation in 6 European countries
Strokes cause an estimated annual health care burden of 170 billion euros across Europe. Atrial fibrillation is one of the major risk factors for stroke and increases the individual risk 4.2-fold. But preventi...
Source: Health Economics Review - February 26, 2022 Category: Health Management Authors: Steffen Wahler, Ralf Birkemeyer, Dimitrios Alexopoulos, Zbigniew Siudak, Alfred M üller and Johann-Matthias von der Schulenburg Tags: Research Source Type: research

Quality of life and cost consequence of delays in endovascular treatment for acute ischemic stroke in China
This study eva...
Source: Health Economics Review - January 6, 2022 Category: Health Management Authors: Weiyi Ni, Wolfgang G. Kunz, Mayank Goyal, Lijin Chen and Yawen Jiang Tags: Research Source Type: research

A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
With atrial fibrillation (AF) the risk of stroke is 4.2-fold increased to a comparable population without AF. This risk decreases by up to 70% if AF is detected early enough and effective stroke preventive mea...
Source: Health Economics Review - June 9, 2020 Category: Health Management Authors: Ralf Birkemeyer, Alfred M üller, Steffen Wahler and Johann-Matthias von der Schulenburg Tags: Research Source Type: research

Erratum to: ‘Quality of life and costs of spasticity treatment in German stroke patients’
Source: Health Economics Review - August 31, 2016 Category: Health Management Authors: Reinhard Rychlik, Fabian Kreimendahl, Nicole Schnur, Judith Lambert-Baumann and Dirk Dressler Source Type: research

Quality of life and costs of spasticity treatment in German stroke patients
To gather data about the medical and non-medical health service in patients suffering from post-stroke spasticity of the upper limb and evaluate treatment effectiveness and tolerability as well as costs over t...
Source: Health Economics Review - July 8, 2016 Category: Health Management Authors: Reinhard Rychlik, Fabian Kreimendahl, Nicole Schnur, Judith Lambert-Baumann and Dirk Dressler Source Type: research

Costs of treating cardiovascular events in Germany: a systematic literature review
Conclusion: MI, unstable angina, HF, stroke and PAD have a high financial impact on the German health care system. Treatment costs of these diseases are mostly incurred during the acute phase of events and tend to decrease over time. Hospitalization and rehabilitation costs were two major cost drivers. Medication costs was one of the smallest cost component reported.
Source: Health Economics Review - September 23, 2015 Category: Health Management Authors: Tamara Schmid Source Type: research

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce.We performed a cost-effe...
Source: Health Economics Review - June 26, 2015 Category: Health Management Authors: Mariano GiorgiChristian CaroliNorberto GiglioPaula MiconeEleonora AielloCristina VulcanoJulia BlancoBonnie DonatoJoaquin Quevedo Source Type: research